TBH Stock Chart & Stats
€114.30
-€2.50(-2.14%)
At close: 4:00 PM EDT
€114.30
-€2.50(-2.14%)
Day’s Range― - ―
52-Week Range€85.00 - €120.10
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€5.25B
Enterprise Value€7.66K
Total Cash (Recent Filing)€309.41M
Total Debt (Recent Filing)€2.69B
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 06, 2026EPS Estimate
1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.80
Shares Outstanding44,270,210
10 Day Avg. Volume11
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€130.70Price Target Upside14.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)5.79
Revenue Forecast (FY)€1.98B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating and free cash flow provides durable internal funding for operations, R&D and capital allocation. This cash cushion supports planned debt reduction and buybacks, reducing reliance on external financing and improving long-term financial flexibility even while GAAP earnings are stressed.
Material Divestiture Proceeds PlannedProceeds from announced divestitures materially reshape the balance sheet and funding capacity. The $1.8B is earmarked for share repurchases and ~$800M debt paydown, which will lower leverage, reduce interest burden and free capital to focus on core vascular, interventional and surgical franchises long-term.
Experienced CEO And Board RefreshA permanent CEO with deep industry and vascular experience strengthens execution capability for the company’s strategic pivot. Leadership with relevant commercial and product-launch expertise increases odds of smoother integration, faster commercialization and better operational discipline across the refocused portfolio.
Bears Say
Severe Profitability DeteriorationDeep negative margins and negative EBITDA signal fundamental earnings weakness that can persist beyond short-term cycles. Sustained losses erode retained capital, depress returns on equity and constrain reinvestment capacity, making margin recovery and credible long-term profitability the central execution risk.
Material Margin Compression And Remediation CostsLarge margin headwinds from tariffs, supplier remediation and higher distribution costs materially reduce sustainable operating profitability. These structural cost pressures, plus lower-margin acquisition mix and stranded costs, can depress adjusted margins and cash flow for multiple quarters absent successful restructuring.
Regulatory/timing Risk To Strategic ProceedsRegulatory reviews and potential delays to divestiture closings threaten the timing of ~$1.8B proceeds. A postponed or altered sale timeline would delay debt reduction and buybacks, keep leverage and interest costs elevated, and extend exposure to stranded costs and integration disruption.
TBH FAQ
What was Teleflex Inc’s price range in the past 12 months?
Teleflex Inc lowest stock price was €85.00 and its highest was €120.10 in the past 12 months.
What is Teleflex Inc’s market cap?
Teleflex Inc’s market cap is €5.25B.
When is Teleflex Inc’s upcoming earnings report date?
Teleflex Inc’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Teleflex Inc’s earnings last quarter?
Teleflex Inc released its earnings results on May 07, 2026. The company reported €1.22 earnings per share for the quarter, beating the consensus estimate of €1.066 by €0.155.
Is Teleflex Inc overvalued?
According to Wall Street analysts Teleflex Inc’s price is currently Undervalued.
Does Teleflex Inc pay dividends?
Teleflex Inc does not currently pay dividends.
What is Teleflex Inc’s EPS estimate?
Teleflex Inc’s EPS estimate is 1.12.
How many shares outstanding does Teleflex Inc have?
Teleflex Inc has 44,270,210 shares outstanding.
What happened to Teleflex Inc’s price movement after its last earnings report?
Teleflex Inc reported an EPS of €1.22 in its last earnings report, beating expectations of €1.066. Following the earnings report the stock price went up 3.128%.
Which hedge fund is a major shareholder of Teleflex Inc?
Currently, no hedge funds are holding shares in DE:TBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€130.70 (14.35% Upside)
€130.70 (14.35% Upside)
Blogger Sentiment
Bullish
DE:TBH Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.98%
12-Months-Change
Fundamentals
Return on Equity
1.01%
Trailing 12-Months
Asset Growth
-5.31%
Trailing 12-Months
Company Description
Teleflex Inc
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TBH Company Deck
TBH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.View all DE:TBH earnings summariesTBH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€130.70
▲(14.35% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―











